Final Program

112 SUNDAY • MAY 15
clinician and researcher to stay current. However, health care providers who deal
with children must be informed of the most recent advances and evidence-based
care practices. Pediatric Year in Review will present a scholarly discussion of
several of the most important and influential papers in key clinical topic areas
published within the past two years. Experts in their respective fields will discuss the
selected papers and allow time for discussion.
Chairing: M. Rosenfeld, MD, MPH, Seattle, WA
A.C. Koumbourlis, MD, MPH, Washington, DC
2:15 Sleep Medicine
E.S. Katz, MD, Boston, MA
2:45 Bronchiectasis in Children
A. Chang, MBBS, PhD, Brisbane, Australia
3:15 Pediatric Pulmonary Genetics and Genomics
L.M. Nogee, MD, Baltimore, MD
3:45 Sickle Cell Disease
A. Greenough, MBBS, MD, London, United Kingdom
A82
There will be a 5-minute discussion after each talk.
CLINICAL
SCIENTIFIC SYMPOSIUM
CME Credits Available: 2.0
TREATMENT OF EARLY STAGE AND
SCREEN-DETECTED LUNG CANCER:
A PRO/CON DEBATE
Assemblies on Thoracic Oncology; Behavioral Science and Health
Services Research; Clinical Problems
2:15 p.m. - 4:15 p.m. MOSCONE CENTER
Room 303/305 (South Building, Esplanade Level)
Target Audience
Clinicians who care for patients with lung cancer; researchers and policy makers
interested in thoracic oncology;patients and family members of patients with lung
cancer.
Objectives
At the conclusion of this session, the participant will be able to:
• determine when to refer patients for limited resection versus lobectomy for
stage I NSCLCa;
• learn new findings about the role of SBRT for treatment of early stage NSCLCa;
• improve discussions around appropriateness of therapy for non-solid lung
cancers.
Early stage lung cancer accounts for ~15% of cases. However, a considerable
increase in the number of cases is expected based on the new USPSTF guidelines
for CT screening. The optimal treatment of patients with stage I non-small cell lung
cancer, and screen-detected malignancies in particular, is unclear. Using a pro-con
debate approach, this session will address key questions such as: what are the
indications for limited resection for lung cancer ≤ 2 cm in size, cancer ≤ 2 cm in
size,, what is the role of SBRT for clinically and screen detected cancers, and what is
the best management of subsolid cancers identified via screening.
Chairing: J.P. Wisnivesky, MD, New York, NY
G. Veronesi, MD, Milan, Italy
R.S. Wiener, MD, MPH, Boston, MA
2:15 PRO: Limited Resection Should Be the Standard of Care for
Stage I Non-Small Cell Lung Cancer £ 2 cm in Size
F.C. Detterbeck, MD, New Haven, CT
2:35 CON: Limited Resection Should Be the Standard of Care for
Stage I Non-Small Cell Lung Cancer £ 2 cm in Size
A.A. Balekian, MD, MS, Los Angeles, CA
2:55 PRO: SBRT Should Be the Standard of Care for Early Stage
NSCLCa Patients at High Risk for Resection
P. Mazzone, MD, MPH, Cleveland, OH
3:15 CON: SBRT Should Be the Standard of Care for Early Stage
NSCLCa Patients at High Risk for Resection
C.G. Slatore, MD, Portland, OR
3:35 PRO: Subsolid Screen-Detected Lung Cancers Should Not Be
Treated
G.A. Silvestri, MD, MS, Charleston, SC
3:55 CON: Subsolid Screen-Detected Lung Cancers Should Not Be
Treated
G. Veronesi, MD, Milan, Italy
This session and the International Conference are supported by an educational grant from
AstraZeneca LP.
All CME sessions have been planned and implemented in accordance with the Essential
Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME)
and are free of the control of commercial interests.
A83
CLINICAL
CLINICAL TOPICS IN PULMONARY MEDICINE
CME Credits Available: 2.0
GREAT CASES: CLINICAL, RADIOLOGIC, AND
PATHOLOGIC CORRELATIONS BY MASTER
PHYSICIANS
Council of Chapter Representatives
2:15 p.m. - 4:15 p.m. MOSCONE CENTER
Room 134 (North Building, Lower Level)
Target Audience
Clinicians in the fields of pulmonary and critical care medicine, pediatric
pulmonology, sleep medicine, thoracic surgery, and infectious disease.
Objectives
At the conclusion of this session, the participant will be able to:
• integrate the clinical presentation, radiologic and pathologic findings for 7
challenging cases;
• understand the clinical reasoning used to determine differential diagnosis
by master clinicians using a multidisciplinary approach;
• describe the associated pathology and radiology of the cases.
Learners will have the opportunity to observe master clinicians approach
challenging clinical problems by working through 7 unknown cases selected
from the abstract pool. Collaboration with a master radiologist reviewing the
films and a master pathologist reviewing pathology slides will demonstrate the
multidisciplinary approach to difficult cases. The audience will participate though
ATS 2016 • San Francisco